Publication: Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers
Submitted Date
Received Date
Accepted Date
Issued Date
2018-06-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
18729096
01663542
01663542
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85045462667
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Antiviral Research. Vol.154, (2018), 58-65
Citation
Tatsuhiko Ozawa, Hideyuki Masaki, Tomohiko Takasaki, Ikuko Aoyama, Takahiro Yumisashi, Atsushi Yamanaka, Eiji Konishi, Yoh Ohnuki, Atsushi Muraguchi, Hiroyuki Kishi (2018). Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/46011.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Series
Has Part
Abstract
© 2018 Elsevier B.V. West Nile virus (WNV) is a positive-sense single-stranded RNA flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex of the Flaviviridae family and causes mosquito-borne infections. Although most human infection cases are asymptomatic, approximately one in 150 infected individuals develops meningoencephalitis, with a mortality rate of 4–14%. While the development of human neutralizing antibody therapeutics against WNV is strongly anticipated, WNV is difficult to study in conventional laboratories due to its high safety level requirement. In this study, we established fully human WNV-neutralizing monoclonal antibodies from the peripheral blood mononuclear cells of inactivated-JEV-vaccinated individuals, and these antibodies exhibited WNV neutralization both in vitro and in vivo. Our results demonstrate a new antibody cross-reactivity strategy to develop immunological therapeutic reagents for WNV and other JEV serotype viruses.